Marksans Pharma Limited

Equities

MARKSANS

INE750C01026

Pharmaceuticals

Market Closed - NSE India S.E. 07:40:51 2024-09-20 am EDT 5-day change 1st Jan Change
318.35 INR +16.00% Intraday chart for Marksans Pharma Limited +18.77% +97.61%
LockThis article is reserved for members
To unlock the article, REGISTER!
Vous êtes déja client ? Log In
Marksans Pharma Arm Gets UK Regulator's Marketing Nod for Fluoxetine Capsules MT
Marksans Pharma Gets US FDA's EIR for Goa, India Unit MT
Successful Closure of US FDA Inspection At Marksans Pharma's Manufacturing Facility Located At Verna, Goa CI
Marksans Pharma Seeks M&A CI
Marksans Pharma Limited, Q1 2025 Earnings Call, Aug 14, 2024
Marksans Pharma Limited Reports Earnings Results for the First Quarter Ended June 30, 2024 CI
Marksans Pharma Arm Gets UK Regulator's Nod for Levonorgestrel Tablet MT
Marksans Pharma Gets UK Regulator's Nod for Two Products MT
Marksans Pharma Limited, Q4 2024 Earnings Call, May 31, 2024
INDIA STOCKS-Indian shares fall for fifth session on weak global cues, election uncertainties RE
Marksans Pharma's Consolidated Profit Declines in Fiscal Q4; Shares Fall 9% MT
Marksans Pharma Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024 CI
Marksans Pharma Limited Recommends Final Dividend for the Financial Year 2023-24 CI
Marksans Pharma Gets Marketing Approval for Levetiracetam Relonchem in UK MT
Marksans Pharma's Goa Facility Gets Five Inspectional Observations from US FDA MT
Marksans Pharma Limited Presents at Bharat Connect Conference - Rising Stars 2024, Mar-26-2024
Marksans Pharma Limited, Q3 2024 Earnings Call, Feb 14, 2024
Marksans Pharma Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Marksans Pharma Limited, Q2 2024 Earnings Call, Nov 09, 2023
Marksans Pharma Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Marksans Pharma Arm Gets UK Regulator's Approval to Market Cyanocobalamin Tablets MT
Marksans Pharma Undergoes Successful Inspection from German Health Authorities MT
CARE Affirms A+ Rating on Marksans Pharma's Long-term Bank Financing; Outlook Stable MT
Marksans Pharma Gets US FDA Nod for Esomeprazole Magnesium Delayed-Release Capsules MT
Marksans Pharma Limited Announces US FDA Approval for Esomeprazole Magnesium Delayed-Release Capsules USP, 20 mg CI
Chart Marksans Pharma Limited
More charts
Logo Marksans Pharma Limited
Marksans Pharma Limited is an India-based company, which is engaged in research, manufacturing and marketing of generic pharmaceutical formulations in the global markets. The Company's product portfolio spreads various therapeutic segments of cardiovascular system (CVS), central nervous system (CNS), antidiabetic, pain management, cough and cold, gastroenterological, and anti-allergies. Its product portfolio includes tablets (plain, enteric-coated and film-coated), hard capsules, soft gelatin capsules, oral liquids and ointments. Its consumer self-care products (over the counter) include pain management, upper respiratory, digestive health, vitamins minerals and supplements (VMS) and skin care products. The Company's prescription - Rx therapeutic segments include CVS, CNS, oncology, anti-diabetics and anti-biotic. Its end consumers include retail chains, pharmacy stores, hospitals and institutions. It has manufacturing facilities in India, the United Kingdom and the United States.
Employees
1,141
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
318.35INR
Average target price
261.33INR
Spread / Average Target
-17.91%
Consensus

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. MARKSANS Stock
  4. News Marksans Pharma Limited
  5. Marksans Pharma Gets UK Regulator's Nod for Two Products